Clinical Protocols

Evidence grading for pharmacological, nutritional, and physical interventions based on human trial data, not murine models.

Pharmacological Nutritional Physical

Evidence Tier System

Tier I Robust RCTs demonstrating human healthspan/lifespan extension. (Currently empty).

Tier II Strong human biomarker data; clear mechanism of action; active Phase II/III trials.

Tier III Observational human data or strong primate data; conflicting or early RCTs.

Tier IV Murine/in-vitro only. Unproven in humans. (Not listed).

Pharmacological Interventions

Tier II mTOR Inhibitor

Rapamycin (Sirolimus)

FDA approved immunosuppressant currently undergoing trials for geroprotection via mTORC1 inhibition.

View Full Clinical Data

Typical Off-Label Dosing

5-8mg orally, once weekly.

Pulsed dosing used to avoid mTORC2 inhibition and mitigate immunosuppression.

Primary Biomarker Targets

mTORC1 activity (proxy)
Inflammatory cytokines
Visceral adiposity

Clinical Trial Status: PEARL Trial (Participatory Evaluation of Aging with Rapamycin for Longevity) - Phase II active.

Tier III Biguanide

Metformin

First-line Type 2 Diabetes medication with observed geroprotective effects in retrospective epidemiological studies.

Typical Off-Label Dosing

500mg - 1000mg extended release, daily.

Primary Biomarker Targets

Fasting Glucose
HbA1c
AMPK activation

Recent Update: Recent ITP (Interventions Testing Program) data showed negligible lifespan extension in mice when started in middle age. TAME (Targeting Aging with Metformin) trial pending funding. Evidence downgraded from Tier II to Tier III.